Gabamide
![]() | |
Clinical data | |
---|---|
Other names | GABAmide; GABAMIDE; GABA amide; 4-Aminobutanamide; 4-ABAD; 4-Aminobutyramide; gamma-Aminobutyramide; γ-Aminobutyramide; GABAD; gamma-Aminobutyric acid amide; γ-Aminobutyric acid amide |
Drug class | GABA receptor agonist |
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.019.852 |
Chemical and physical data | |
Formula | C4H10N2O |
Molar mass | 102.137 g·mol−1 |
3D model (JSmol) | |
| |
|
Gabamide, or GABAmide, also known as γ-aminobutyramide (GABAD), is a GABA receptor agonist and GABA analogue, or more specifically the amide of the inhibitory neurotransmitter γ-aminobutyric acid (GABA).[1][2] Along with GABA and progabide acid (SL-75.102), gabamide is an active metabolite of the anticonvulsant drug progabide (Gabrene; SL-76.002).[1][2] Unlike progabide, but similarly to GABA, gabamide is unable to cross the blood–brain barrier and hence is peripherally selective.[2] However, gabamide and GABA are formed in the brain from progabide following its entry into this part of the body.[2]
See also
[edit]- γ-Amino-β-hydroxybutyric acid (GABOB)
- γ-Hydroxybutyrate (GHB)
References
[edit]- ^ a b Bartholini G (1981). "Present Knowledge of GABA Receptor Agonists". Medicinal Chemistry Advances. Elsevier. pp. 345–353. doi:10.1016/b978-0-08-025297-1.50032-5. ISBN 978-0-08-025297-1. Retrieved 6 October 2025.
- ^ a b c d Bergmann KJ (1985). "Progabide: a new GABA-mimetic agent in clinical use". Clinical Neuropharmacology. 8 (1): 13–26. doi:10.1097/00002826-198503000-00002. PMID 2983890.
Progabide, a new synthetic compound defined as the Schiff base of gamma-aminobutyramide and a substituted benzophenone, has been developed. Well absorbed, and relatively free of toxicity, it is both a direct GABA receptor agonist as well as an exogenous source of GABA. [...]